Christopher Schmidt, PA
Medical · Terre Haute, INNPI 1881005213
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 305 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Novo Nordisk at 24.1% of the total. Reporting peaked in 2023 at $1,468 and has fallen 52.9% since, to $691 in 2025.
Across 305 payments — averaging $14.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$559
- AbbVie$555
- Lilly USA, LLC$406
- Bayer$240
- GSK$198
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,23499%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 103 | $1,030 |
| AstraZeneca | 22 | $559 |
| AbbVie | 45 | $555 |
| Lilly USA, LLC | 31 | $406 |
| Bayer | 16 | $240 |
| GSK | 13 | $198 |
| Pfizer | 9 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $121 |
| Amgen | 6 | $102 |
| Exact Sciences | 5 | $98 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $95 |
| Teva Pharmaceuticals USA, Inc. | 5 | $92 |
| Novartis | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $74 |
| Merck | 5 | $74 |
| Boehringer Ingelheim | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 3 | $62 |
| Mylan Specialty L.p. | 2 | $40 |
| Lundbeck LLC | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Axonics, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Corium, LLC | 2 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Halozyme Inc | 1 | $13 |
| Genentech USA, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,274 in reported general payments places this provider in the 85th percentile of 273 medical providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $145,582 |
| JardianceEmpagliflozin | 97 | $134,022 |
| TrulicityDulaglutide | 62 | $77,050 |
| MounjaroTirzepatide | 69 | $74,566 |
| EliquisApixaban | 80 | $72,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $66,387 |
| JanuviaSitagliptin Phosphate | 58 | $50,800 |
| FarxigaDapagliflozin Propanediol | 49 | $48,371 |
| VraylarCariprazine Hcl | 25 | $46,099 |
| LinzessLinaclotide | 16 | $23,277 |
| CreonLipase/Protease/Amylase | 12 | $22,125 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $21,493 |
| TrintellixVortioxetine Hydrobromide | 20 | $19,222 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $18,445 |
| RexultiBrexpiprazole | 12 | $17,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $406 | $151,616131 claims |
| Boehringer IngelheimJardiance, Tradjenta | $73 | $147,983112 claims |
| Novo NordiskOzempic | $1,030 | $145,582137 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $198 | $96,040139 claims |
| AbbVieVraylar, Linzess, Creon, Synthroid | $555 | $94,18591 claims |
| PfizerEliquis | $144 | $72,31980 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $559 | $69,86575 claims |
| MerckJanuvia | $74 | $50,80058 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $121 | $19,22220 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $24 | $11,26613 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $7,62928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 273 medical providers in Indiana.
Other medical in Terre Haute
- Taylor StoneTerre Haute$5K
- Briseida Oceguera PerezTerre Haute$5K
- Jacklyn SloverTerre Haute$2K
- Meggie BeckleyIndianapolis$125K
- Jennifer ConnerIndianapolis$98K
- Brandon BoydCarmel$46K
- Karey DavisNew Castle$45K
- Sheryl NewCarmel$39K
- Lindsey GradyValparaiso$39K
- Jennifer IrwinIndianapolis$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.